Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10026292 | 0.90 | PRKCA (0.50) | PRKCALMNAALDH1A1MAPTPRKCE | |
| SCHEMBL19506623 | 0.90 | ALDH1A1 (0.53) | PRKCALMNAALDH1A1PRKCEPRKCQ | |
| SCHEMBL6370166 | 0.90 | PRKCA (0.50) | PRKCALMNAALDH1A1MAPTPRKCE | |
| SCHEMBL10130615 | 0.88 | PRKCA (0.65) | PRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL10135101 | 0.85 | PRKCA (0.47) | PRKCALMNAALDH1A1MAPTPRKCE | |
| SCHEMBL14007345 | 0.84 | ENPP2 (0.45) | PRKCALMNAALDH1A1PRKCEPRKCQ | |
| SCHEMBL10231802 | 0.84 | ENPP2 (0.45) | PRKCALMNAALDH1A1PRKCEPRKCQ | |
| SCHEMBL3800572 | 0.83 | ENPP2 (0.44) | PRKCALMNAALDH1A1PRKCEPRKCQ | |
| SCHEMBL19300984 | 0.83 | PRKCA (0.44) | PRKCALMNAALDH1A1MAPTPRKCE | |
| SCHEMBL19300629 | 0.82 | PRKCA (0.56) | PRKCALMNAALDH1A1MAPTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283816-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-9738899-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170211083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2017-07-27 | — | — | US | disclosed |
| US-20130012567-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2013-01-10 | — | — | US | disclosed |
| EP-2278004-B1 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1458741-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID | SIRNA THERAPEUTICS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8273866-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8268986-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2287306-B1 | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8242257-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20090099116-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090093435-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GRB2 ASSOCIATED BINDING PROTEIN (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090023675-A1 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080207542-A1 | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080161256-A1 | Treating Hepatitis B Virus (HBV) with Adefovir Dipivoxil in combination with a chemically synthesized double stranded nucleic acid; toxicologic properties while retaining RNAi activity | SIRNA THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080039414-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIMA THERAPEUTICS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032942-A1 | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) | MCSWIGGEN JAMES | 2008-02-07 | — | — | US | disclosed |
| US-20070160980-A1 | Each double stranded siNA sequence is between 19 and 23 nucleotides, directs gene cleavage, has a complementary antisense region, and is derived from a virus chosen from HIV, hepatitis, respiratory syncytial virus (RSV) or influenza; gene therapy | SIRNA THERAPEUTICS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070042983-A1 | Use as antisense agent; chemically synthesized siNA with first sense strand and second antisense strand, said strands form an asymmetric duplex | SIRNA THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1741781-A2 | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) | Sirna Therapeutics, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283816-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PRKCA 2538/4885LMNA 3645/4885ALDH1A1 2776/4885 |
| US-20090099116-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | FOS, FOSB, NFATC1 | PRKCA 652/4885LMNA 4637/4885ALDH1A1 3664/4885 |
| US-20070042983-A1 | Use as antisense agent; chemically synthesized siNA with first sense strand and second antisense strand, said strands form an asymmetric duplex | AGO2, POLI, MSI2 | PRKCA 3275/4885LMNA 2931/4885ALDH1A1 3194/4885 |
| US-20080207542-A1 | RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA) | AGO2, HNRNPC, HAVCR2 | PRKCA 973/4885LMNA 557/4885ALDH1A1 2354/4885 |
| US-20090023675-A1 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) | AGO2, SNRPE, SRRT | PRKCA 2538/4885LMNA 3645/4885ALDH1A1 2776/4885 |
| US-20170211083-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PRKCA 2538/4885LMNA 3645/4885ALDH1A1 2776/4885 |
| US-20080161256-A1 | Treating Hepatitis B Virus (HBV) with Adefovir Dipivoxil in combination with a chemically synthesized double stranded nucleic acid; toxicologic properties while retaining RNAi activity | ADAR, POLI, EIF2AK2 | PRKCA 3295/4885LMNA 2931/4885ALDH1A1 3298/4885 |
| US-20090093435-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GRB2 ASSOCIATED BINDING PROTEIN (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | GAB1, GRB2, ING2 | PRKCA 608/4885LMNA 4600/4885ALDH1A1 3920/4885 |
| US-20080039414-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | PRKCA 3441/4885LMNA 4413/4885ALDH1A1 1659/4885 |
| US-20080032942-A1 | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) | PSEN1, PSEN2, BACE2 | PRKCA 3192/4885LMNA 1455/4885ALDH1A1 4299/4885 |
| US-20130012567-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | PRKCA 2538/4885LMNA 3645/4885ALDH1A1 2776/4885 |
| US-20070160980-A1 | Each double stranded siNA sequence is between 19 and 23 nucleotides, directs gene cleavage, has a complementary antisense region, and is derived from a virus chosen from HIV, hepatitis, respiratory syncytial virus (RSV) or influenza; gene therapy | SRRT, RNASE1, SNRPE | PRKCA 3729/4885LMNA 1288/4885ALDH1A1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.